Shots:

• The approval is based on P-III AUGUMENT study involves assessing of Revlimid + Rituximab (R²) vs rituximab +PBO in patients with previously treated follicular lymphoma (FL) or marginal zone lymphoma (MZL)
• The study resulted improvement in 1EP mPFS (39.4 mos. vs 13.8 mos.) with median follow up 29.2 months. Additionally- the safety and efficacy of Revlimid + Rituximab in patients with relapsed or refractory FL including rituximabrefractory FL patients was supported by MAGNIFY study
• Revlimid (lenalidomide) + rituximab is the first chemotherapy-free combination regimen for patients with FL who have relapsed or did not respond to previous treatment and approved in the US- Canada- Switzerland- Australia- New Zealand and several Latin American countries

Click here to read full press release/ article

Ref: BMS | Image: BMS